| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC7023 | Ombrabulin Featured | Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors. |
|
| DC10054 | Ombrabulin hydrochloride Featured | Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors. |
|
| DC11044 | Omidenepag Isopropyl Featured | Omidenepag Isopropyl (DE-117, OMDI) is the prodrug of Omidenepag, which is a potent, selective agonist human EP2 receptor; demonstrates excellent IOP-lowering activities following ocular administration in ocular normotensive monkeys, Omidenepag Isopropyl (OMDI) is a clinical candidate for the treatment of glaucoma. |
|
| DC10043 | ONO4059 hydrochloride Featured | ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM. |
|
| DC8358 | ONO-4059(Tirabrutinib) Featured | ONO-4059 is a novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase. |
|
| DC11905 | Opiranserin Featured | Opiranserin (VVZ-149, VVZ-000149) is a potent, selective, mixed glycine GlyT2 transporter blocker (IC50= 0.86 uM), purine P2X3 receptor antagonist (IC50=0.87 uM) and serotonin 5-HT2A receptor antagonist (IC50=1.3 uM). |
|
| DC2010 | Oprozomib (ONX-0912) Featured | Oprozomib (ONX 0912) selectively inhibits CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. |
-chemical-structure.gif)
|
| DC10394 | Org-26576 | Org 26576 is a AMPA receptor positive allosteric modulator. |
|
| DC11203 | ORIC-101 Featured | ORIC-101 (ORIC101) is a highly potent, selective steroidal glucocorticoid receptor (GR) antagonist (IC50=5.6 nM) with reduced androgen receptor (AR) agonistic activity. |
|
| DC23149 | Oseltamivir acid | Oseltamivir acid (GS 4071, Ro 64-0802, Oseltamivir carboxylate) is a potent inhibitor of influenza neuraminidase (NA) with Ki of <1 nM for both A and B strains,showed potent activity against COVID-19(SARS-COV-2). |
|
| DCAPI1594 | Oseltamivir phosphate Featured | OSELTAMIVIR is an active (orally) inhibitor of the influenze virus neuraminidase and converted to the active acid metabolite in vivo. |
|
| DC1006 | OSI-027 Featured | OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively. |
|
| DC4105 | Linsitinib(OSI-906) Featured | OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R and IR with IC50 of 35 nM and 75 nM, respectively. |
|
| DC7219 | OSI 930 Featured | OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl. |
|
| DC8248 | Ostarine(MK-2286) Featured | Ostarine (MK-2866) is a selective androgen receptor modulator (SARMs) that regulates cardiomyocyte function, improves bone healing, regulates uterine function, and influences muscle tissue metabolism. |
|
| DC7220 | OSU-03012 Featured | OSU-03012(AR-12) is a potent inhibitor of recombinant PDK-1 with IC50 of 5 μM and 2-fold increase in potency over OSU-02067. |
|
| DC9443 | Otamixaban | Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. |
|
| DC7109 | Otenabant (CP-945598 free base) Featured | Otenabant (CP945598) is a recently discovered selective, high affinity, competitive CB1 receptor antagonist with Ki of 0.7 nM. |
|
| DC8732 | OTSSP167 Featured | OTSSP167 is a highly potent MELK inhibitor (IC50 = 0.41 nM) and inhibited the phosphorylation of PSMA1 (proteasome subunit alpha type 1) and DBNL (drebrin-like). |
|
| DC7475 | OTSSP167 HCl Featured | OTSSP167 is a highly potent MELK inhibitor (IC50 = 0.41 nM) and inhibited the phosphorylation of PSMA1 (proteasome subunit alpha type 1) and DBNL (drebrin-like). |
|
| DC5885 | Oxaliplatin Featured | Oxaliplatin is a second generation potent platinum-based anti-neoplastic agent that is believed to form inter- and intrastrand DNA adducts which activate signaling pathways culminating in apoptosis. The development of Oxaliplatin was inspired from the eff |
|
| DC8281 | Ozanimod (RPC1063) Featured | Ozanimod (RPC1063) is a selective S1P1R modulator |
|
| DC10399 | PAC-14028 | PAC-14028 is a potent and selective transient receptor potential vanilloid type I (TRPV1) antagonist. |
|
| DC11113 | Padsevonil | Padsevonil (UCB-0942, UCB0942) is a potential anti-seizure agent that functions as a pre- and post-synaptic inhibitor.. |
|
| DC10292 | Pagoclone | Pagoclone is an active (+)-enantiomer of the racemate RP 59037. Pagoclone is a partial GABA(A) receptor agonist used for the treatment of panic and anxiety disorders. |
|
| DC8717 | PAK4-IN-1（KPT9274） Featured | PAK4-IN-1 is an inhibitor of p21-activated kinases (PAKs), with IC50 of ≤100 nM in MTT assay. |
|
| DC8469 | Palbociclib Featured | Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. |
|
| DC5067 | Palbociclib (PD0332991 HCl) Featured | Palbociclib is an oral, small molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, now in Phase 3 clinical development for advanced breast cancer. |
|
| DC7970 | ACT058362 (Palosuran) Featured | Palosuran (ACT-058362) is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM. |
|
| DC9681 | Pamapimod（R-1503） Featured | Pamapimod（R-1503）is a novel p38 MAP kinase inhibitor. |
|
